p53 is a tetrameric protein with a thermodynamically unstable deoxyribonucleic acid (DNA)-binding domain flanked by intrinsically disordered regulatory domains that control its activity. The unstable and disordered segments of p53 allow high flexibility as it interacts with binding partners and permits a rapid on/off switch to control its function. The p53 tetramer can exist in multiple conformational states, any of which can be stabilized by a particular modification. Here, we apply the allostery model to p53 to ask whether evidence can be found that the "activating" C-terminal phosphorylation of p53 stabilizes a specific conformation of the protein in the absence of DNA. We take advantage of monoclonal antibodies for p53 that measure indirectly the following conformations: unfolded, folded, and tetrameric. A double antibody capture enzyme linked-immunosorbent assay was used to observe evidence of conformational changes of human p53 upon phosphorylation by casein kinase 2 in vitro. It was demonstrated that oligomerization and stabilization of p53 wild-type conformation results in differential exposure of conformational epitopes PAb1620, PAb240, and DO12 that indicates a reduction in the "unfolded" conformation and increases in the folded conformation coincide with increases in its oligomerization state. These data highlight that the oligomeric conformation of p53 can be stabilized by an activating enzyme and further highlight the utility of the allostery model when applied to understanding the regulation of unstable and intrinsically disordered proteins.

Institute of Biophysics Academy of Sciences of the Czech Republic Brno 612 65 Czech Republic

Institute of Genetics and Molecular Medicine Edinburgh Cancer Research Centre Cell Signaling Unit University of Edinburgh Edinburgh EH4 2XR United Kingdom

p53 Laboratory Singapore 138648 Singapore

RECAMO Masaryk Memorial Cancer Institute Brno 65653 Czech Republic

School of Chemical and Biomedical Engineering Nanyang Technological University Singapore 637457 Singapore

Zobrazit více v PubMed

Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307–310. PubMed

Fields S, Jang SK (1990) Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046–1049. PubMed

Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C (1993) A proteolytic fragment from the central region of p53 has marked sequence‐specific DNA‐binding activity when generated from wild‐type but not from oncogenic mutant p53 protein. Genes Dev 7:2565–2574. PubMed

Halazonetis TD, Kandil AN (1993) Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants. EMBO J 12:5057–5064. PubMed PMC

Wang P, Reed M, Wang Y, Mayr G, Stenger JE, Anderson ME, Schwedes JF, Tegtmeyer P (1994) P53 domains: Structure, oligomerization, and transformation. Mol Cell Biol 14:5182–5191. PubMed PMC

Hupp TR, Meek DW, Midgley CA, Lane DP (1992) Regulation of the specific DNA binding function of p53. Cell 71:875–886. PubMed

Tompa P (2012) On the supertertiary structure of proteins. Nat Chem Biol 8:597–600. PubMed

Neduva V, Linding R, Su‐Angrand I, Stark A, de Masi F, Gibson TJ, Lewis J, Serrano L, Russell RB (2005) Systematic discovery of new recognition peptides mediating protein interaction networks. PLoS Biol 3:e405. PubMed PMC

Wright PE, Dyson HJ (1999) Intrinsically unstructured proteins: Re‐assessing the protein structure‐function paradigm. J Mol Biol 293:321–331. PubMed

Hilser VJ (2010) Biochemistry. An ensemble view of allostery. Science 327:653–654. PubMed PMC

Maslon MM, Hrstka R, Vojtesek B, Hupp TR (2010) A divergent substrate‐binding loop within the pro‐oncogenic protein anterior gradient‐2 forms a docking site for reptin. J Mol Biol 404:418–438. PubMed

Uversky VN, Oldfield CJ, Dunker AK (2008) Intrinsically disordered proteins in human diseases: Introducing the d2 concept. Annu Rev Biophys 37:215–246. PubMed

Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, Proctor MR, Lane DP, Fersht AR (1997) Thermodynamic stability of wild‐type and mutant p53 core domain. Proc Natl Acad Sci USA 94:14338–14342. PubMed PMC

Hupp TR, Lane DP (1994) Allosteric activation of latent p53 tetramers. Curr Biol 4:865–875. PubMed

Sakaguchi K, Sakamoto H, Lewis MS, Anderson CW, Erickson JW, Appella E, Xie D (1997) Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry 36:10117–10124. PubMed

Nichols NM, Matthews KS (2002) Human p53 phosphorylation mimic, s392e, increases nonspecific DNA affinity and thermal stability. Biochemistry 41:170–178. PubMed

Bruins W, Zwart E, Attardi LD, Iwakuma T, Hoogervorst EM, Beems RB, Miranda B, van Oostrom CT, van den Berg J, van den Aardweg GJ, Lozano G, van Steeg H, Jacks T, de Vries A (2004) Increased sensitivity to uv radiation in mice with a p53 point mutation at ser389. Mol Cell Biol 24:8884–8894. PubMed PMC

Hoogervorst EM, Bruins W, Zwart E, van Oostrom CT, van den Aardweg GJ, Beems RB, van den Berg J, Jacks T, van Steeg H, de Vries A (2005) Lack of p53 ser389 phosphorylation predisposes mice to develop 2‐acetylaminofluorene‐induced bladder tumors but not ionizing radiation‐induced lymphomas. Cancer Res 65:3610–3616. PubMed

Yakovleva T, Pramanik A, Kawasaki T, Tan‐No K, Gileva I, Lindegren H, Langel U, Ekstrom TJ, Rigler R, Terenius L, Bakalkin G (2001) p53 latency. C‐terminal domain prevents binding of p53 core to target but not to nonspecific DNA sequences. J Biol Chem 276:15650–15658. PubMed

Ayed A, Mulder FA, Yi GS, Lu Y, Kay LE, Arrowsmith CH (2001) Latent and active p53 are identical in conformation. Nat Struct Biol 8:756–760. PubMed

McKinney K, Mattia M, Gottifredi V, Prives C (2004) P53 linear diffusion along DNA requires its c terminus. Mol Cell 16:413–424. PubMed

Dornan D, Shimizu H, Burch L, Smith AJ, Hupp TR (2003) The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA‐dependent acetylation of p53. Mol Cell Biol 23:8846–8861. PubMed PMC

Češková P, Chichger H, Wallace M, Vojtesek B, Hupp TR (2006) On the mechanism of sequence‐specific DNA‐dependent acetylation of p53: The acetylation motif is exposed upon DNA binding. J Mol Biol 357:442–456. PubMed

Cox ML, Meek DW (2010) Phosphorylation of serine 392 in p53 is a common and integral event during p53 induction by diverse stimuli. Cell Signal 22:564–571. PubMed

Pospisilova S, Brazda V, Kucharikova K, Luciani MG, Hupp TR, Skladal P, Palecek E, Vojtesek B (2004) Activation of the DNA‐binding ability of latent p53 protein by protein kinase c is abolished by protein kinase ck2. Biochem J 378:939–947. PubMed PMC

Meek DW, Cox M (2011) Induction and activation of the p53 pathway: A role for the protein kinase ck2?. Mol Cell Biochem 356:133–138. PubMed

Bruins W, Bruning O, Jonker MJ, Zwart E, van der Hoeven TV, Pennings JL, Rauwerda H, de Vries A, Breit TM (2008) The absence of ser389 phosphorylation in p53 affects the basal gene expression level of many p53‐dependent genes and alters the biphasic response to uv exposure in mouse embryonic fibroblasts. Mol Cell Biol 28:1974–1987. PubMed PMC

Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, Goodman R, Lozano G, Zhao Y, Lu H (2001) A DNA damage‐induced p53 serine 392 kinase complex contains ck2, hspt16, and ssrp1. Mol Cell 7:283–292. PubMed

Hupp TR (1999) Regulation of p53 protein function through alterations in protein‐folding pathways. Cell Mol Life Sci 55:88–95. PubMed PMC

Gotz C, Scholtes P, Prowald A, Schuster N, Nastainczyk W, Montenarh M (1999) Protein kinase ck2 interacts with a multi‐protein binding domain of p53. Mol Cell Biochem 191:111–120. PubMed

Jagelska E, Brazda V, Pospisilova S, Vojtesek B, Palecek E (2002) New ELISA technique for analysis of p53 protein/DNA binding properties. J Immunol Methods 267:227–235. PubMed

Appella E, Anderson CW (2000) Signaling to p53: Breaking the posttranslational modification code. Pathol Biol 48:227–245. PubMed

Friedman PN, Chen X, Bargonetti J, Prives C (1993) The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci USA 90:3319–3323. PubMed PMC

Hamard PJ, Barthelery N, Hogstad B, Mungamuri SK, Tonnessen CA, Carvajal LA, Senturk E, Gillespie V, Aaronson SA, Merad M, Manfredi JJ (2013) The C terminus of p53 regulates gene expression by multiple mechanisms in a target‐ and tissue‐specific manner in vivo. Genes Dev 27:1868–1885. PubMed PMC

Harlow E, Lane D (2006) Antibody purification on protein a or protein g columns. CSH Protoc 2006:pdb.prot4283. PubMed

Vojtĕsek B, Bártek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237–244. PubMed

Dolezalova H, Vojtesek B, Kovarik J (1997) Epitope analysis of the human p53 tumour suppressor protein. Folia Biol 43:49–51. PubMed

Pospisilova S, Kankova K, Svitakova M, Nenutil R, Vojtesek B (2001) New monoclonal antibodies recognizing p53 protein phosphorylated by casein kinase ii at serine 392. Folia Biol 47:148–151. PubMed

Wang PL, Sait F, Winter G (2001) The ‘wildtype’ conformation of p53: Epitope mapping using hybrid proteins. Oncogene 20:2318–2324. PubMed

Milner J, Cook A, Sheldon M (1987) A new anti‐p53 monoclonal antibody, previously reported to be directed against the large t antigen of simian virus 40. Oncogene 1:453–455. PubMed

Vojtesek B, Dolezalova H, Lauerova L, Svitakova M, Havlis P, Kovarik J, Midgley CA, Lane DP (1995) Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene 10:389–393. PubMed

Gannon JV, Greaves R, Iggo R, Lane DP (1990) Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595–1602. PubMed PMC

Wittig I, Braun HP, Schagger H (2006) Blue native page. Nat Protoc 1:418–428. PubMed

Harlow E, Lane D (2006) Indirect detection using horseradish peroxidase‐labeled reagents. CSH Protoc 2006:pdb.prot4296. PubMed

Characterization of p53 Family Homologs in Evolutionary Remote Branches of Holozoa